FDA OKs First-in-Class Sotatercept for PAH

Sotatercept with background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone in the STELLAR trial.

Related Keywords

United States ,Boston ,Massachusetts ,Aaron Waxman ,World Heart Federation ,American College Of Cardiology ,World Health Organization ,Drug Administration ,Pulmonary Heart Diseases ,Functional Class ,American College ,Thenew England Journal ,